NCT07367815RecruitingPhase 1/2
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
Allogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I/II Trial
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- 7 May 2026
- Primary completion date
- 1 May 2029
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Alzheimer disease
- NCT number
- NCT07367815
- EU CT number
- 2022-502846-28-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 9
- From 7 May 2026 to the primary completion date, 1 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of concomitant pathologies not permitting participation in the study
- Concurrent participation in other research that may influence the testing of the A3D study
- PET scan performed in the previous year (research context)
- Presence of \> 4 brain microbleeds, a single area of superficial siderosis, or evidence of previous macrohaemorrhage assessed by brain MRI scan
- Regular use of corticosteroids or other steroidal anti-inflammatory drugs (e. g. prednisone)
Other illness
- Brain disease (other than AD) that may cause dementia
- Carrier of a pacemaker, valve prosthesis or other internal magnetic or electronic system, history of neurosurgery or aneurysm surgery, presence of metal fragments in the eyes, brain or marrow, claustrophobia
- History of cancer diagnosed within the last 5 years
- Presence of an autoimmune disease (e. g. rheumatoid arthritis, systemic lupus erythematosus) with the exception of psoriasis
- Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision For patients who will participate in the optional adipose puncture (only carried out in the Toulouse center): Antithrombotic treatment and xylocaine allergy are prohibited.
Other
- Pregnant or breastfeeding woman
Who the study is looking for
- Patient between 50 and 85 years old
- AD diagnosis according to NIA-AA 2011 criteria at a mild to moderate stage :
- MMSE score between 14 and 26 (include) positive AD amyloid biomarker
- CDR (clinical dementia rating) score ≥ 1
- Patient with no absolute contraindications for PET or MRI scans
- Consent signed by the patient and study partner
- presence of primary caregiver
- Patient with social security coverage
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.